Gynecologic Oncology News & Updates

A compilation of news articles in the field of gynecologic oncology and recent scientific studies

Ten years on, Professor Ian Frazer recalls ‘lucky’ discovery of cervical cancer vaccine
March 25, 2017: Professor Frazer recently spoke at the World Science Festival in Brisbane, Australia and was interviewed regarding his team’s discovery of the cervical cancer vaccine. Read the highlights from the interview.

Adjuvant and systemic therapy for rare tumors of the uterus and cervix
March 25, 2017: HemOnc Today offers practical advice on the treatment of rare diseases of the uterus and cervix by summarizing the latest research in a commentary written by Drs. Erin Crane, Jubilee Brown and Wendel Naumann. Read the commentary.

What all women need to know about gynecologic cancers
March 24, 2017: Health reporter Diane Atwood writes about her friend’s experience with stage III fallopian tube cancer and interviews gynecologic oncologist, Dr. Emmanuel Soultanakis, providing a complete summary of signs, symptoms and risk factors for gynecologic cancers. Read the blog.

Cancer survivors more likely to have preterm birth, cesarean delivery
March 23, 2017: Dr. Hazel B. Nichols is interviewed by HemOnc Today regarding her research that suggests women treated with chemotherapy may have increased risk for preterm birth in the future. Read the interview.

Combination yields ‘promising’ results for recurrent, BRCA-deficient ovarian cancer
March 23, 2017: An interview with Dr. Sarah Adams (University of New Mexico) regarding the phase 2 clinical trial studying combination treatment of olaparib (lynparza, AstraZeneca) and tremellimumab. Read the interview.

A call for molecular profiling in uterine carcinosarcoma
March 22, 2017: OncLive interviews Dr. Douglas Levine regarding the recent published paper in Cancer Cell, which charted the biology of 57 patients with uterine carcinosarcoma. Dr. Levine states that the “results really call for molecular profiling of this rare-type of tumor.” Read the interview.

Research into talcum powder – ovarian cancer link reveals troubling differences based on study designs
March 21, 2017: HemOnc Today interviews Dr. Paolo Boffeta regarding his team’s systematic review and meta-analysis evaluating the association between genital talcum powder use and ovarian cancer risk. Boffeta says that evidence falls short from demonstrating a casual link. Read the interview.

Hormonal maintenance therapy prolongs PFS for serous carcinoma of ovary, peritoneum
March 20, 2017: HemOnc Today interviews Dr. David Gershenson regarding the findings of a retrospective study that show “women with stage II to stage IV low-grade serous carcinoma of the ovary or peritoneum demonstrated longer PFS when treated with hormonal maintenance therapy after primary chemotherapy rather than routine observation.” Read the interview.

Hamad Medical Center holds first Qatar gynecologic malignancy symposium
March 20, 2017: The symposium addressed important issues in women’s cancer with a focus on the development of collaborative research and training in the GCC and MENA region. Read the press release.

Oral apixaban safe for thromboprophylaxis before surgery in gynecologic cancers
March 17, 2017:  Presented at SGO 2017 by Dr. Saketh Guntupalli, “Thromboprophylaxis with oral apixaban was similar to subcutaneous enoxaparin with regard to safety outcomes in women undergoing surgery for suspected gynecologic malignancies. The oral medication may provide an option that would increase compliance and satisfaction in this setting.” Read the CancerNetwork article.

Readmission rates after gynecologic surgery may not be a valid measurement of quality care
March 16, 2017: Two studies presented at SGO 2017 indicate “Surgeons should focus on long-term outcomes for the treatment of ovarian cancer rather than hospital readmission rates after surgery.” Read the Healio.com article.

Priority symptoms identified in recurrent ovarian cancer
March 16, 2017: Presented at SGO 2017, the National Cancer Institute and National Academy of Sciences have identified 18 core symptoms that should be assessed among patients with recurrent OC. Read this news article to learn the symptoms.

Immunotherapy motolimod fails to improve survival in ovarian cancer
March 15, 2017: Data presented by Dr. Bradley Monk at SGO 2017: “The addition of the immune therapy motolimod to pegylated liposomal doxorubicin (PLD) failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial. There was a survival advantage, however, specifically in patients who experienced injection site reactions, which could help guide the use of this therapy.” Read the CancerNetwork article. 

Sentinel lymph node mapping cost-effective in endometrial carcinoma
March 15, 2017: “Sentinel lymph node (SLN) mapping is cost-effective compared with other methods of lymphadenectomy (LND) in the management of low-risk endometrial carcinoma, according to a decision analysis model study presented at the 2017 SGO Annual Meeting.” Read more.

Integrated molecular characterization of uterine carcinosarcoma
March 2017: This integrated genomic and proteomic analysis of 57 uterine carcinosarcomas provides insights into disease biology and offers therapeutic opportunities. Read the full text.

Advaxis presents oral late-breaking data on phase II GOG-0265 study of Axalimogene Filolisbac
March 15, 2017: Data presented at the 2017 SGO Annual Meeting: “Unprecedented 12-month survival rate for metastatic cervical cancer observed” Read the press release. Read the Medpage Today story on the same study.

Gene expression signature predicts outcomes in endometrial cancer
March 14, 2017: “A 7-transcript classifiers (MS7) effectively predicted metastatic disease for patients with endometrioid endometrial cancer (EEC), with added promise shown when the gene expression signature was combined with pathologic features, according to findings presented at the 2017 SGO Meeting.” Read more.

MMR deficiency linked to PD-L1 expression in endometrial cancer
March 14, 2017: “Mismatch repair (MMR)–deficient endometrial cancers exhibited significantly higher levels of PD-L1 expression compared with MMR-intact tumors, according to a poster presentation at the 2017 SGO Annual Meeting.” Read more.

Reduction strategies improve surgical site infection rate after colon surgery
March 14, 2017: “Introduction of a surgical site infection (SSI) reduction bundle significantly improved 30-day SSI rates among gynecologic cancer patients undergoing colon surgery, according to a study presented at the 2017 SGO Annual Meeting.” Read more.

Niraparib maintenance results have paradigm-shifting potential in ovarian cancer
March 14, 2017:  Targeted Oncology interviewed Dr. Kathleen Moore and Dr. Ursula Matulonis at the 2017 SGO Annual Meeting,  discussing the use of PARP inhibitors such as niraparib for the treatment of ovarian cancer – advances that could be practice changing. Read the interview with Dr. Moore. Read the interview with Dr. Matulonis. 

Carboplatin desensitation leads to improved OS in ovarian cancer
March 14, 2017: Patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen had an improved overall survival (OS), according to a retrospective analysis reported at the 2017 SGO Annual Meeting on Women’s Cancer.” Read more.

Maintenance chemo after CR fails to extend survival in ovarian cancer
March 14, 2017: Presented at the 2017 SGO Annual Meeting on Women’s Cancer: “A long-term phase III randomized trial found that maintenance chemotherapy did not improve overall survival over surveillance among women with advanced ovarian/fallopian tube/peritoneal cancer who had a complete response (CR) to first-line therapy. Maintenance chemotherapy also increased toxicity in these patients.” Read more.

LYNPARZA™ (olaparib) phase III SOLO-2 data demonstrated progression-free survival benefit in BRCA-mutated ovarian cancer as maintenance therapy
March 14, 2017: AstraZeneca shares results of Phase III trial: “The SOLO-2 data demonstrated a statistically significant and clinically meaningful improvement in outcomes for those who took olaparib. The results, which showed a delay in disease progression in the maintenance setting, highlight the impact of PARP inhibition at the forefront of the important advances we are making in targeting ovarian cancer.” Read the full press release. Read the Healio.com story. Read the MedPage Today story.

Enhanced Recovery after surgery for ovarian cancer patients
March 14, 2017: A cancernetwork.com interview with Dr. Robert Neff regarding his data presented at the 2017 SGO Annual Meeting on Women’s Cancer that compared the cost-effectiveness of an enhanced recovery program compared with usual care following patients who had surgical cytoreduction for their ovarian cancer. Read or listen to the interview.

Three doses of HPV vaccine no more beneficial than two
March 13, 2017: Presented at SGO 2017, investigators observed no significant difference in outcomes between patients who received 2 doses of the vaccine and those who received 3 doses. Read the article.

Gynecologic Oncologists cite time, money as barriers to global health participation
March 12, 2017: “Lack of clinical coverage and time off topped the perceived hindrances to gynecologic oncologists’ participation in global health activities, according to a study reported at the Society of Gynecologic Oncology (SGO) in National Harbor, MD.” Read more.

Research shows vitamin B3 reduces pain from chemotherapy induced peripheral neuropathy
March 10, 2017: “Rats given prophylactic daily doses of nicotinamide riboside at 200 mg/kg 7 days prior to chemotherapy and continuing for 24 days after the termination of chemotherapy did not experience peripheral nerve hypersensitivity.” Read more.

Reversion mutations may predict chemotherapy response in recurrent serous ovarian cancer
March 7, 2017: “The detection of reversion BRCA1 or BRCA2 mutations among women with recurrent high-grade serous ovarian cancer predicted response to chemotherapy treatment, according to study results.” Read more.

Study shows platelets can deliver immunotherapy, reduce tumor regrowth
March 3, 2017: A new NCI study suggests that blood platelets engineered to deliver an immunotherapy drug may effectively eliminate cancer cells missed by surgery and prevent them from forming new tumors. Read the NCI blog.

Ovarian cancer target molecule may be key to blocking its spread
March 2, 2017: “Blocking a protein found on the surface of ovarian cancer cells could prevent or reduce the spread of the disease to other organs, according to new research.” Read more.

The Pap smear: groundbreaking, lifesaving  – and obsolete?
March 1, 2017: With new ways to collect data, including HPV testing, is the Pap past it’s prime? Read more.

Lowering GI Toxicities in Gynecologic Cancers
March 1, 2017: “Intensity-modulated radiation therapy (IMRT) proved to lower the incidence of gastrointestinal toxicities in patients with gynecologic malignancies, according to the results from a recent study.” Read more.

NEJM: The changing face of clinical trials
March 2017: A collection of articles that examine the current challenges in the design, performance, and interpretation of clinical trials. Read the collection.

Controlled interventions to reduce burnout in physicians: a systematic review and meta-analysis
February 2017:  This meta-analysis of 20 controlled interventions on 1550 physicians found that existing interventions were associated with small and significant reductions in burnout. The strongest evidence for effectiveness was found for organization-directed interventions, but these interventions were rare. Read more.

Special issue in Clinical Oncology: Radiotherapy in low and middle income countries
February 2017: the Feb. special issue of Clinical Oncology includes an editorial and several studies and analysis of radiotherapy in low and middle income countries. See the issue.

Ovarian cancer screening has some benefits in high-risk women
February 28, 2017: “Screening for ovarian cancer in high-risk patients led to detection of significantly more early-stage disease as compared with the 1 year after screening ended, a multicenter study showed.” Read more.

Evolution of surgical management optimizes care for patients with rare gynecologic tumors
February 25, 2017:  This commentary reiterates that “significant progress has been made in the treatment of rare gynecologic cancers over the past decade, and clinicians should be aware of these advances in order to provide optimal patient care.” Read more.

Low recurrence after risk-reducing surgery for BRCA carriers
February 24, 2017: Dr. Maurie Markman discusses a paper that appeared in the journal Gynecologic Oncology, entitled “Occult and Subsequent Cancer Incidence Following the Risk-Reducing Surgery in BRCA Mutation Carriers.” Read more.

Researcher finds safer, less invasive method of staging endometrial cancer
February 24, 2017: “Emma Rossi, MD, in the UNC Department of Obstetric and Gynecology’s Division of Gynecologic Oncology, has published a study in Lancet Oncology online that identifies sentinel-lymph-node mapping as a safer and less-invasive method of staging endometrial cancer that is equally as accurate as the more traditional lymphadenectomy.” Read more.

Researchers use genetics to identify cancer recurrence risk
February 22, 2017:  University of Wisconsin-Madison researcher, Christine Kendziorski and her team of researchers have identified a set of genetic traits that indicate a person may have a relapse of ovarian cancer. Read more.

Hormonal maintenance therapy may improve survival in women with chemo-resistant rare ovarian or peritoneum cancer
February 21, 2017: For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance therapy (HMT) may significantly improve survival, according to a new study from researchers at The University of Texas MD Anderson Cancer Center. Read more.

Read archived news stories.

Indian National Gynecologic Cancer Day

March 11th is recognized in India as the National Day of Gynecologic Cancers as endorsed by the Federation of Obstetric & Gynaecological Societies of India, The Association of Gynecologic Oncologists of India, The Association of Radiation Oncologists of India, The Indian Society of Oncology and the Indian Association of Surgical Oncology.

This date was chosen as it falls in the same week of International Women’s Day (March 8th).

Due to the lack of public education and awareness regarding these cancers, variable pathology, and scarcity of proper screening facilities in developing countries such as India, most women report at advanced stages, adversely affecting the prognosis and clinical outcomes. A data summary of published Indian data regarding gynecologic cancers was recently compiled by the South Asian Journal of Cancer.

 

IGCS applauds the work these societies are doing to raise awareness for gynecologic cancers, encouraging education regarding prevention and screening practices for early detection of all gynecologic cancers!

President’s Perspective March 2017

Dear Colleagues,

One of the many outstanding benefits of being a member of our Society is access to our professional journal the International Journal of Gynecologic Cancer (IJGC) which is jointly published by IGCS and ESGO.  IJGC has allowed us to build a collective knowledge base and play a vital role in the archive of knowledge, and in forming a comprehensive, up-to-date, authoritative body of information.

The journal has provided a unique repository for researchers and clinicians in the field of gynecologic oncology to submit and read information specific to our specialty.  Because of the work of the editorial team, our peer review process serves as one of the most important mechanisms for validating the information contained in our journal and is the widely-accepted indicator of quality scholarship and expected standards of academic rigour. The Editorial Board has provided an extraordinary commitment to ensuring that the quality of the published papers is world standard. On your behalf, I thank them for their incredible work.

Recently our Editor-in-Chief, Dr. Uzi Beller made the decision to step down after more than ten years of service. Uzi’s ongoing aim has been to constantly improve the quality of the journal. He has demonstrated this by reducing the time to publication dramatically and by enhancing the quality of the finished product so that there is an annual improvement in the Impact Factor, which is the main objective measure of overall excellence . We owe Uzi and his editorial team a great deal of gratitude and praise for their commitment and dedication to publishing the best science possible in IJGC. The effect of this has seen a huge increase in submissions and an enormous change in the spread of countries whose researchers want to publish with us. We are truly an international journal, unique in our specialty.

The position of Editor-in-Chief for IJGC is a prestigious and honoured role, recognizing an individual’s proven abilities and his/her knowledge in the discipline of gynecological oncology.  Strong leadership, interpersonal and organizational qualities will be needed along with a broad network of professional contacts. There is much responsibility for ensuring an important part of the Societies’ obligations to their memberships and the greater gynecological oncology community, but I am confident the role will be personally and professionally rewarding.

Many of you – our members – are excellent candidates for this position. IGCS is lucky enough to have many experts and thought leaders in gynecological oncology with a broad background in basic science and clinical medicine. The Societies will provide the Editor-in-Chief with the essential resources and tools to be successful; if you are interested in the position, please read more about the role and submit your application by March 31, 2017.

I am very appreciative for all that you (as members of IGCS) have and will continue to contribute to IJGC. If I can answer any questions or be of any resource, please do not hesitate to contact me at quinnmichaelam@gmail.com.  It is my privilege and honour to serve as President of your society.

Sincerely,

 

 

Michael Quinn, MA, MGO
2016-2018 IGCS President

Read the Current Issue of IJGC

ijgc_logotxt

IJGC is the scientific publication for topics relevant to detection, prevention, diagnosis, and treatment of gynecologic malignancies. IJGC emphasizes a multidisciplinary approach, and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. The list of associate editors represents every part of the globe and all the major disciplines involved in treating cancer. Preview the current issue (March, 2017) table of contents here.

IGCS Members
Sign in to the IGCS Member Portal and click through to the Journal to gain full access to the articles.

N0t an IGCS Member?
Join today to obtain online access to IJGC.

Prof. Joo-Hyun Nam Celebrates Retirement

Professor Joo-Hyun Nam from Seoul, Korea hosted his retirement meeting on February 10th and 11th at the 2nd International Symposium on Gynecologic Oncology at the Asan Medical Center in Seoul. Professor Nam is a past member of IGCS Council and has made an enormous contribution to teaching and training, particularly in minimally invasive surgery, across the globe. His many friends in IGCS send him warm wishes for a healthy and happy retirement and thank him for such an amazing career.

Renew Membership

Dear Colleague,

Over the course of the last year the IGCS has grown in its promise as the premier global association for gynecologic oncologists and multidisciplinary team members caring for women with gynecologic malignancies. We are proud of our recent achievements and are confident you have noticed our enhancements and accomplishments.

Within the past ten months, IGCS has:

  • Hosted one our most successful Biennial Meetings in Lisbon, Portugal with over 2500 attendees
  • Redesigned and launched of a state-of-the-art website including a robust education portal and members-only section
  • Revitalized the Education Committee with truly international participation
  • Provided support to ten collaborative meetings
  • Developed and launched a global curriculum training program
  • Enhanced our relationship with our industry colleagues to ensure continued development of therapeutics for our patients
  • Recruited a seasoned and professional CEO

Help IGCS continue its mission to enhance the care of women with gynecologic cancer worldwide through education, training and public awareness.
Please submit your 2017 IGCS Membership dues today.

The IGCS relies on the strength of our membership and dues payments to remain an active and vital part of the global gynecologic cancer community. By renewing your membership, you will continue to contribute, participate and benefit from the IGCS in many ways. Without your participation, the Society could not fulfill its mission to provide you and other members with the education and resources necessary to improve the lives of women diagnosed with gynecologic cancers.

As our 2017 dues campaign comes to a close, it has come to our attention that you have not renewed your membership. We hope this is an oversight and that you will submit your dues payment by the end of February. With the launch of our new website, submitting dues online is very safe and convenient. Simply login with your email address and password at https://igcs.org/member-dues/.

Your email address is your username and all member’s passwords were reset to the default password of “unite” with the launch of the new website on October 28th. If you have changed your password since that date, use the new password you created. If you would like, Laura Snitzer, the membership services staff liaison can be reached at laura.snitzer@igcs.org. She would be happy answer any questions or set up a time and walk you through the process.

Membership offers you opportunities to engage with issues affecting the profession, connect with local and global colleagues, access top-tier educational resources and the latest insights. By paying your dues and being a member of IGCS you can assist us in shaping a brighter and stronger future for gynecologic oncology patients and their families.

We look forward to your continued participation in IGCS. We need you.

Sincerely,

 
Michael Quinn, AM, MGO
IGCS President 
 
Mary Eiken, RN, MS
IGCS CEO 

Education Portal Launch

We are thrilled to announce that the online Education Portal is now available in the member’s section of www.igcs.org. Please view this video announcement from IGCS Education Committee Chair, Dr. Kathleen Schmeler.

To access the portal, click on the “members” button at the top right of the IGCS website, sign in and then click “Education Portal.” In the IGCS education portal, members will find:

  • Webcasts from the 2016 and 2014 Biennial Meetings
  • Surgical videos that were playing in the exhibit hall during the 2016 Biennial Meeting
  • Education Exchange videos
  • Blogs written by members of the committee providing commentary on articles published in the International Journal of Gynecological Cancers

The library of videos and resources will continue to grow over time as the IGCS Education Committee identifies and develops educational content. We hope that you find the materials in the Education Portal to be of value and we thank you for being a member of the IGCS.

Please email igcs@igcs.org for assistance.

Education Exchange Preview

In these recorded Education Exchange videos, listen to Drs. Michael Quinn, Usha Menon, Marie Plante, and Frederic Amant discuss issues related to gynecologic cancer in a global setting.

Dr. Michael Quinn: Gynecologic Cancer Prevention: A Reality

Dr. Usha Menon: Are We Able To Effectively Screen For Ovarian Cancer

Dr. Marie Plante: Neoadjuvant Chemotherapy For Preservation Of Fertility For Cervical Cancer

Dr. Frederic Amant: Cancer During Pregnancy

World Cancer Day

February 4th is World Cancer Day

Cancer continues to devastate peoples’ lives and destroy their futures. By 2030 it is estimated that the number of global cancer cases will rise to 21 million from 12.7 million. We in the international cancer community are very aware of the devastating statistics and the resultant significant challenges that our patients and cancer professionals face daily. Limited resources, late diagnoses, high mortality rates, and rising cancer incidence, particularly in settings that can least afford cancer care, remind us that there is still a huge amount of work to be done, especially as the cancer burden is over-represented in low economy countries.

We applaud and continue to support the Union for International Cancer Control (UICC) for its ongoing efforts to raise awareness of cancer control and prevention and congratulate them for their continued efforts. IGCS as an organization has parallel goals to raise awareness of the actions needed to prevent and treat gynecologic cancers. IGCS is proud to support all the efforts being conducted in connection with World Cancer Day February 4, 2017.

While we as individuals can play our part, global, regional, and national policies and programs are needed to assist in accomplishing our collective goals.  Unless we take swift, collective action to raise awareness about cancer prevention, and practical strategies are put into place, millions of people will continue to suffer. The UICC has an excellent information tool kit for all of us to get involved and show our support locally for World Cancer Day.

We are proud to be adding our organizational resources and extensive commitment from you, our members to accomplishing our goals. We continue to make education our top priority along with training in low to middle resource areas. Our education committee will be launching our new education portal in the next several days and included in there is a wealth of gynecologic cancer information. We have posted a preview of some of our Education Exchange videos for World Cancer Day.

Our mission constantly challenges us to be an impactful organization in relieving the burden of cancer globally, and we can achieve this by extending World Cancer Day beyond one day and make it a part of our lives every day.

We invite you to join us in the journey.

 
Michael Quinn, AM, MGO
IGCS President 
 
Mary Eiken, RN, MS
IGCS CEO 

Gynecologic Oncology News Archive

A compilation of news articles in the field of gynecologic oncology and recent scientific studies

Two studies bring bad news about cervical cancer deaths and HPV – So what can we do?

February 17, 2017: The importance of screening and vaccination – and less stigma. Read more.

LEEP rather than freeze to prevent cervical cancer

February 15, 2017:  “HIV-infected women who develop high-risk cervical lesions and undergo loop electrosurgical excisional procedures (LEEP) had less risk of recurrence or of cervical cancer than similar women in resource-poor settings treated with cryotherapy.” Read more.

Analyzing copies of genes may offer new therapeutic approaches for ovarian cancer

February 15, 2017: “A team of 18 University of California San Diego School of Medicine and Moores Cancer Center researchers has developed a new tool to analyze an often overlooked aspect of cancer genetics — an alteration that results in the loss or gain in a copy of a gene. This change, known as somatic copy-number alterations, may be key to disease progression and might offer new therapeutic approaches for ovarian cancer and other malignancies.” Read more.

Study links ovarian cancer growth to gene defects

February 14, 2017:   Defects in a key gene—long thought to drive cancer by turning off the protection afforded by the BRCA genes—spur cancer growth on their own, according to a study led by researchers from NYU Langone Medical Center The study gene, known as EMSY, has some of the same functions as BRCA1 and BRCA2 and helps explain why some women with healthy BRCA1 and BRCA2 genes develop cancer. Read more.

BRCA reversion mutations in cfDNA can predict response in ovarian cancer

February 14, 2017:  A small study found that it is feasible to detect BRCA1/2 reversion mutations in circulating cell-free DNA (cfDNA) in patients with recurrent high-grade serous ovarian cancer (HGSC). Those reversion mutations can help predict poor response to therapy in these patients. Read more.

Mayo Clinic Program Examines ovarian cancer applications for liquid biopsy

February 10, 2017: “The goal of the Ovarian Cancer Project is to identify biomarkers that can be used to treat ovarian cancers that have not responded to conventional treatments such as debulking and chemotherapy. By customizing treatment, interventions may be more effective at achieving a cure. In addition, the program is working to identify biomarkers that can be used to follow patients over time, allowing early identification of ovarian cancer recurrence.” Read more.

Retroperitoneal exploration improves survival in optimally debulked advanced epithelial ovarian cancer.

February 6, 2017: “Retroperitoneal exploration at the time of primary debulking surgery appeared to improve survival in patients with intraperitoneal stage IIIC optimally debulked epithelial ovarian cancer, according to data collected from a large multi-institutional trial.” Read more.

Dr. Levine on combos with PARP inhibitors in ovarian cancer

February 3, 2017: Dr. Douglas Levine on OncLive discusses combining PARP inhibitors with chemotherapy as well as the question of when and how to give them. View the video.

Diagnostic laparascopies can prevent future surgeries in ovarian cancer

February 1, 2017: A study published in the Journal of Clinical Oncology shows that “the number of futile laparotomies was decreased in patients with advanced stage ovarian cancer who underwent diagnostic laparoscopies.” Read more.

Homologous recombination deficiency analysis predicts PARP inhibitor benefit for ovarian cancer

January 27, 2017: “Next-generation sequencing used to detect homologous recombination deficiency may predict responses to rucaparib in patients with BRCA wild-type platinum-sensitive ovarian cancers, according to results from the international, multicenter, open-label phase 2 trial ARIEL2 study.” Read more.

Lynch syndrome – associated ovarian cancer presents early, has good prognosis

January 25, 2017: An analysis of Lynch syndrome–associated ovarian cancer published in Gynecologic Oncology found that the malignancy tends to present at an early stage and has a generally good prognosis. Ovarian surveillance may be useful in some women to detect this malignancy early. Read more.

Murine study finds potential boost for ovarian cancer drug Olaparib

January 25, 2017: “Researchers have discovered that the metabolic enzyme phosphoglycerate mutase 1 (PGAM1) helps cancer cells repair their DNA and found that inhibiting PGAM1 sensitizes tumors to the cancer drug Olaparib (Lynparza). Their findings suggest that this FDA-approved ovarian cancer medicine has the potential to treat a wider range of cancer types than currently indicated.” Read more about this study.

TCGA study identifies genomic features of cervical cancer

January 24, 2017: A news release from the National Institutes of Health announces “investigators with The Cancer Genome Atlas (TCGA) Research Network have identified novel genomic and molecular characteristics of cervical cancer that will aid in the subclassification of the disease and may help target therapies that are most appropriate for each patient.” Read more.

Study pinpoints opportunity for oncologists to improve communication with patients.

January 24, 2017: A study published in the Journal of Oncology Practice looked at doctor-patient conversations and found that doctors naturally avoid difficult discussions about a challenging prognosis. This shows there may be missed opportunities to discuss what test results actually mean and allow the patient and family members to process and explore the situation. Read more.

Cervical cancer deaths rates are much higher than previously thought

January 23, 2017: “Black women are dying from cervical cancer at a rate 77% higher than previously thought, and white women are dying at a rate 47% higher, according to a study published in the journal Cancer. The study found that previous estimates of cervical cancer death rates didn’t account for women who had their cervixes removed in hysterectomy procedures, which eliminates the risk of developing the cancer.” Read more.

Endometrioid ovarian cancer presents earlier, offers better survival than serous carcinoma

January 20, 2017: “Women with endometrioid ovarian cancer present at a younger age and with earlier stage disease than those with serous ovarian cancer, according to a new analysis. The earlier presentation resulted in better 5- and 10-year overall survival rates as well.” Read more.

Countries with limited health care resources need education regarding breast cancer risk factors

January, 2017: Survey reveals there is a need for breast cancer education  in limited resource countries. Read more.

Ovarian conservation may boost outcomes in endometrial cancer

January 18, 2017: MedPage Today (free login required) writes, “Ovarian conservation was associated with decreased long-term all-cause mortality in young women with low-grade, early-stage endometrial cancer,, according to researchers.” Read more.

Why are we still talking about ‘ovarian’ cancer?

January 18, 2017: Seventy-five percent of the most deadly ‘ovarian’ cancer arises in the fallopian tubes. Should the new name for ovarian cancer be pelvic serous carcinoma? Read more.

More Chemo may not equal better outcomes in ovarian cancer

January 16, 2017: MedPage Today (free login required) writes “Increasing, the number of cycles of chemotherapy doesn’t appear to significantly influence recurrence rates or survival in patients with early stage ovarian clear cell carcinoma (OCCC), according to researchers.” Read more.

Assessment identifies patients with endometrial cancer at low risk for lymph node metastasis

January 13, 2017: “Preoperative assessment of lymph node metastasis in endometrial cancer may encourage selective lymphadenectomy for low-risk patients,” according to a study by Dr. Sokbom Kang and colleagues at the Research Institute and Hospital of National Cancer Center in the Republic of Korea. Read more.

Research evaluates treatment options for pelvic organ prolapse

January 12, 2017: Recently published in the American Journal of Obstetrics & Gynecology, research “found that while women undergoing surgery or having a pessary achieve their goals and have improvements in physical, social and emotional functioning, those who underwent surgery experienced greater improvements.” Read more.

Researchers discover new subtype of cervical cancer

January 10, 2017: “A team of University of South Carolina scientists led by Carolyn Banister and Phillip Buckhaults has identified a new subtype of cervical cancer that, like most cervical cancers, is triggered by human papillomavirus (HPV) but whose growth is not directed by the virus, suggesting that therapy targeting these tumors’ distinct genomic pathways may improve patient outcomes over standard treatment.” Read more.

Bush Institute’s recommendations on global health policy

January 10, 2017: The George W. Bush Institute recommends that the US continue to invest in global health initiatives such as HIV and AIDS prevention and treatment and focusing on women’s healthcare. Read more.

Diagnostic laparoscopy to reduce the likelihood of futile laparotomy

January 10, 2017: “Treatment with diagnostic laparoscopy rather than primary surgery may lower the rate of futile laparotomies among women with suspected advanced ovarian cancer according to a study published in the Journal of Clinical Oncology.” Read more.

New clinical trial combines two methods to defeat ovarian cancer

January 9, 2017: A new clinical trial at the University of New Mexico is testing a new approach to defeat ovarian cancer. “The clinical trial treats women whose ovarian cancer results from mutated BRCA genes. It uses one drug that kills the ovarian cancer cells and another that boosts the immune system in response to the dying cancer cells.” Read more.

ASCO updates clinical guideline to include palliative care

January 9, 2017: The key recommendation is that “Patients with advanced cancer, whether inpatient or outpatient, should receive dedicated palliative care services, early in the disease course, concurrent with active treatment.” Read more.

Study shows that BRCA status does not affect survival outcomes in young women with early breast cancer

December 25, 2016: “The study showed that patients with BRCA-positive breast cancer may safely delay bilateral mastectomy, since an immediate bilateral mastectomy within the first year of diagnosis did not affect survival.” Read more.

Endometrial cancer mutations are detectable in uterine lavage fluid before cancer is diagnosed

December 29, 2016: A press release from Newswise highlighted the findings of a study published in PLOS Medicine, “Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study.” Read the article.

CT-planned, high-dose-rate brachytherapy effective in cervical cancer

December 28, 2016: OncLive posted an article summarizing the results of a recent study published in Gynecologic Oncology. Lead author, Akila Viswanathan, MD, Executive Vice Chair, Johns Hopkins Radiation Oncology and Molecular Radiation Sciences wrote in the study: “We found that, of 9 patient characteristics and various RT prognostic factors tested in a univariate analysis, tumor size and total external beam radiation therapy (EBRT) plus BT dose were initially the most significant prognostic factors for predicting any recurrence (AR)” Read the full article.

Combination of Camptosar and Avastin safe and effective for recurrent ovarian cancer

December 27, 2016: MedPage Today reported the findings of a phase II study in the journal Gynecologic Oncology demonstrating that Camptosar and Avastin “may be a safe and effective alternative in heavily pre-treated patients with recurrent ovarian cancer, including those with prior bevacizumab and topoisomerase inhibitor use.” Read the full article.

FDA grants priority review of TESARO’s niraparib for gynecologic cancers

December 21, 2016:  “The FDA granted priority review to niraparib for the treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer following response to platinum-based chemotherapy.” Read more.

Fallopian tubes may have big role to play in ovarian cancer fight

December 20, 2016: CNN posted an article noting that “research increasingly points to the likelihood that some of the most aggressive ovarian cancers originate in the fallopian tubes.” Read more.

FDA grants accelerated approval to rucaparib to treat certain types of ovarian cancer

December 19, 2016: The U.S. Food and Drug Administration granted accelerated approval to Rubraca (rucaparib) to treat “women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as identified be an FDA-approved companion diagnostic test.” Read the press release.  Watch this brief video of Dr. Michael Birrer discussing the treatment.

Leading cause of cancer mortality in the Caribbean region from 2003-2013

December 16, 2016: The Centers for Disease Control and Prevention (CDC) released a report stating the cancer is the second leading cause of mortality in the Caribbean region. “Among females, breast cancer was the most common cause of cancer deaths in 16 of the 18 countries for which data were reported, accounting for 14.0%–29.7% of cancer deaths, followed by cervical cancer, which accounted for 4.5%–18.2% of cancer deaths.” Read the full report.

Early surgery may increase risk of death for some uterine cancer patients

December 16, 2016: MedicalXpress.com published an article referencing a new study in the American Journal of Obstetrics and Gynecology. “In the study, women who had surgery (usually to remove the uterus) within the first two weeks after diagnosis had a significantly increased risk of death within five years, compared to those who had surgery three or four weeks after their initial diagnosis.” Read the full article.

Biomarkers are a top priority in immunotherapy progress in ovarian cancer

December 13, 2016: OncLive published an article interviewing Dr. Maurie Markman regarding the importance of searching for “validated, actionable biomarkers” which “may lead to accelerated approval of…drugs, because of very high response rates in those selected populations.” Read the full interview.

FDA approves Genentech’s Avastin (Bevacizumab) plus chemotherapy for a specific type of advanced ovarian cancer

December 6, 2016: The press release notes “Approval based on two large Phase III studies including GOG-0213 that showed a five month overall survival difference for women with platinum-sensitive recurrent ovarian cancer on Avastin plus chemotherapy compared to chemotherapy alone.” Read the press release.

JAMA publishes a systematic analysis of the global burden of disease

December 3, 2016: The analysis provides global, regional and national cancer incidence and more for 32 cancer groups, including cervical, uterine and ovarian cancer from 1990-2015. The study reports that in 2015, 526,000 women developed cervical cancer worldwide, causing 239,000 deaths. In low service delivery indicator (SDI) countries, 1 in 24 women developed cervical cancer while in high SDI countries 1 in 115 women developed cervical cancer during a lifetime. Read the full analysis.

New York Times publishes article “What Not to Say to a Cancer Patient”

November 28, 2016: The New York times promotes the book “Loving, Supporting, and Caring for the Cancer Patient” which provides helpful suggestions to the friends and family members of cancer patients. Read the article.

JCO study on neoadjuvant chemotherapy

November, 2016: The Journal of Clinical Oncology, the official journal of the American Society of Clinical Oncology (ASCO)  published a study on the use and effectiveness of neoadjuvant chemotherapy for the treatment of ovarian cancer.

The findings of the study “suggest that in carefully selected patients with stage IIIC disease, PCS is associated with a survival advantage, with overall low rates of surgical morbidity. In contrast, for patients with stage IV disease, … results confirm that NACT is noninferior to PCS for survival, with fewer ICU admissions and rehospitalizations, which suggests that NACT may be preferable for patients with stage IV ovarian cancer.”  Read the full JCO study.